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A B S T R A C T   
Invasive pulmonary aspergillosis is a complication in critically ill patients with acute respiratory distress syn-
drome, especially those with severe coronavirus disease-associated pneumonia. In this study, five cases of pre-
sumed invasive pulmonary aspergillosis in one immunocompromised and four immunocompetent patients with 
COVID-19 in Buenos Aires are described. In all cases, the underlying conditions, clinical presentation, fungal 
diagnostic tests used and their results, features of the chest scan images, antifungals used and clinical outcomes 
are detailed.   
1. Introduction 
The coronavirus disease 19 (COVID-19) pandemic, caused by the 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was 
first identified in December 2019 in the Wuhan city, Hubei Province of 
China. This severe respiratory disease is associated with a high mortality 
rate, which varies across different countries. Among the causes of 
morbidity and mortality of patients with COVID-19, invasive pulmonary 
aspergillosis (IPA) emerged as a bad prognosis complication, especially 
in critically ill patients such as those with acute respiratory distress 
syndrome (ARDS) at intensive care units (ICU). In this regard, in many 
European countries, clinicians reported that patients with ARDS trig-
gered by SARS-CoV-2, are prone to IPA even in absence of prior im-
munodeficiency. Reports showed that 19–35% of those critically ill 
patients with COVID-19 have signs of Aspergillus co-infections, which is 
alarmingly high [1–6]. This novel entity, also called CAPA (COVID-19 
associated pulmonary aspergillosis), makes Aspergillus an agent capable 
of further compromising the prognosis of these patients, similar to that 
documented in the Netherlands and Belgium with influenza associated 
pulmonary aspergillosis (IAPA) in critically ill patients [7,8]. In addi-
tion, a study carried out in Toronto in a small autopsy series of patients 
who died in 2003 from severe acute respiratory syndrome (SARS), 
reported that 10% of them had a pulmonary pathology suggestive of IPA 
[9]. As the medical community confronts the ongoing COVID-19 
pandemic, determining whether patients infected with SARS-CoV-2 
develop fungal complications, especially IPA, is crucial. 
Therefore, early detection of CAPA could be a useful tool to optimize 
the therapy of critically ill patients with COVID-19 by administering the 
appropriate antifungal treatment [10]. However, diagnosis of CAPA or 
IPA remains difficult and even underdiagnosed. Bronchoalveolar lavage 
(BAL) fluid galactomannan (GM) testing and culture, which are the most 
sensitive diagnostic tests for IPA in the ICU, are hampered by the 
restricted role of bronchoscopies due to the risk of aerosol generation 
and disease transmission. In addition, renal tropism and injury caused 
by SARS-CoV-2 as well as drug-drug interactions, makes CAPA therapy a 
real challenge. Hence, the use of liposomal amphotericin B should be 
cautiously considered, and the emergence of azole-resistance is another 
hazard to take into consideration [11]. 
In Argentina, the COVID-19 pandemic arrived at the beginning of 
March, and Buenos Aires emerged as a hotspot for this respiratory 
disease. 
Since respiratory deterioration is usually considered to be mostly 
associated to bacterial coinfections rather than fungal infection is that 
appropriate fungal diagnostics are not usually performed and thus CAPA 
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may remain undiagnosed. In the present study, we report and describe 
presumptive invasive aspergillosis in five COVID-19 patients admitted to 
the ICU of a single medical center of Buenos Aires so as to contribute to 
the early suspicion, diagnosis and therapeutic management of these 
aspergillosis diseases in patients with ARDS. Sharing experiences and 
information, make clinicians and mycologists to be better prepared in 
the ICU. 
2. Case series presentation 
All patients reported herein were admitted to the ICU at the Posadas 
Hospital, Buenos Aires, Argentina, had COVID-19 with pulmonary in-
filtrates, received broad-spectrum antibiotics, immunosuppressants or 
corticosteroids (8 mg/day), and required mechanical ventilation due to 
moderate-severe COVID-19 pneumonia. For the diagnosis of CAPA/IPA, 
serum GM testing (GM index > 0.5), fungal cultures of sputum, tracheal 
aspirate (TA), chest computed tomography (CT) scan and GM testing in 
respiratory samples (GM index ≥ 1.0) were carried out. All these pa-
tients had a probable diagnosis of CAPA during the first or second week 
of hospitalization, that matches with the middle and latter stages of the 
COVID-19 disease. All patients received voriconazole or liposomal 
amphotericin B as first-line therapy (Table 1). 
2.1. Case 1 
A 23-year-old man with B-cell acute lymphoblastic leukemia came to 
Posadas Hospital on August 2020 to receive block II of salvage chemo-
therapy. Due to pneumonia associated with febrile neutropenia, a nasal 
swab sample was taken for diagnosis of SARS-CoV-2 infection, with a 
positive result. The patient was given antibacterial treatment (mer-
openem, colistin, amikacin, vancomycin) for 5 days, and stopped 
because of lack of microbiological documentation. However, he 
Table 1 
Patients features.  
Patient Sex Age 
(years) 

















1 M 23 B cell 
acutelymphoblastic 
leukemia 
13 6 multiple bilateral 
GGO, CPP, PNC 
with an air- 
bronchogram at 
the level of the 
right posterior 




Probable Voriconazole Died (HD26) 
Serum GM 
index: 0.9 
TA GM index: 
4.2 






inside, and an 














TA GM index: 
N/A 
3 M 44 illicit drug abuse, 
alcoholism, smoking, 
uncontrolled insulin- 





52 32 multiple bilateral 





LFD in serum: 
positive 
LFD in TA: 
positive 






instability Serum GM 
index: 1.01 
TA GM index: 
N/A 
4 M 69 insuline-dependent 
diabetes 
16 6 N/A Culture: 
A. fumigatus 
(TA) 
LFD in serum: 
positive 
LFD in TA: 
positive 





TA GM index: 
0.25 
5 F 69 diabetes type 2, 
arterial hypertension, 
obesity 
15 13 N/A Culture: 
A. fumigatus 
(TA) 





TA GM index: 
3.17 
GGO: ground glass opacities; CPP: crazy paving pattern; PNC: peripheral nodular consolidations; N/A: not available; TA: tracheal aspirate. 
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persisted with refractory hypoxia despite non-invasive positive pressure 
ventilation. At the contrast-enhanced CT, multiple bilateral ground-glass 
opacities with a crazy paving pattern and some peripheral nodular 
consolidations with an air-bronchogram at the level of the right poste-
rior basal segment of the lung, were observed. 
On hospital day (HD) 13 he was transferred to the ICU requiring 
endotracheal intubation and mechanical ventilation for progressive 
worsening of the radiological picture and moderately severe ARDS with 
a PaO2:FiO2 ratio of 117 mm Hg. 
Despite prone positioning, and neuromuscular blockade, refractory 
hypoxia persisted without response to rescue maneuvers. 
TA and serum samples were positive for galactomannan (GM index 
of 4.2 and 0.9, respectively), and intravenous voriconazole treatment 
was commenced (400 mg/12 h first day, then 200 mg/12 h). 
The patient deceased on HD 26 due to respiratory and hemodynamic 
instability and sepsis (after having received an initial dose of vor-
iconazole initially unavailable in our pharmacy). Autopsy was not per-
formed due to concerns for the risk of contamination. 
2.2. Case 2 
A 57-year-old man, whose underlying disease included bronchiec-
tasis presented to Posadas Hospital in June 2020 with productive cough, 
dyspnea and intermittent fever (>38.5 ◦C) for two weeks. Clinical ex-
amination showed signs of acute respiratory failure, tachypnea and 
hypoxemia. He was diagnosed with COVID-19 by real time PCR of a 
nasal swab sample. On HD 2 chest CT showed emphysema, bilateral 
ground-glass opacities with small nodular infiltrations with air- 
bronchogram inside, and an area with diffuse varicose and cystic 
bronchiectasis in the lower right lobe area. The patient was given anti-
bacterial treatment (piperacillin plus tazobactam) without clinical 
improvement. On HD 3, he was transferred to the ICU requiring endo-
tracheal intubation and mechanical ventilation for progressive wors-
ening of the radiological picture and moderately severe ARDS with a 
PaO2:FiO2 ratio of 148 mm Hg and deterioration of the sensorium. 
Aspergillus fumigatus was cultured from sputum samples. Serum GM 
turned positive (GM index: 0.92). Due to severe liver dysfunction (ALT 
317 U/L, ALT 233 U/L, total bilirubin 4,21 mg/dL) the patient was 
started with antifungal therapy with liposomal amphotericin B (5 mg/ 
kg/day; HD 11) for 14 days. Due to good clinical evolution, it was 
decided to go to the general medical clinic room (HD 25). At the time of 
this report the patient remains well, off anti-fungal therapy, with mild 
dry cough and improved effort tolerance, and no systemic features. 
2.3. Case 3 
A 44-year-old man with a history of illicit drug abuse, chronic 
alcoholism and smoking was admitted to the ICU because of ARDS with 
a PaO2:FiO2 ratio of 164 mm Hg. Among his underlying diseases were 
uncontrolled insulin-dependent type 2 diabetes, arterial hypertension, 
obesity (body mass index: 37 kg/m2) and recurrent furunculosis. 
Real time PCR on AT was tested positive for SARS-CoV-2. On HD 20, 
the patient required endotracheal intubation and mechanical ventilation 
for progressive clinical deterioration and hypoxemia. Chest CT-scan was 
performed and showed multiple bilateral ground-glass opacities with a 
crazy paving appearance with many peripheric nodular consolidations 
with air-bronchograms. 
On HD 31, the patient presented bacteremia by Staphylococcus epi-
dermidis and antibiotic therapy with vancomycin was introduced for 14 
days and stopped because he had no more findings of septic embolil. On 
HD 36, he received fluconazole (200-mg loading dose followed by 100 
mg/day for four days) due to urinary candidiasis caused by Candida 
albicans. Then he had daily febrile records without hemodynamic 
decompensation. Due to a novel episode of bacteremia by S. epidermidis 
thirteen days later (HD 49), empirical antibiotic therapy with mer-
openem and colistin commenced. 
Due to persistence of fever, a new TA was obtained. TA culture on 
Sabouraud agar remained sterile. However, Aspergillus LFD was per-
formed from this respiratory sample and from serum and revealed a 
positive result, for which voriconazole was added to the treatment (400 
mg/12 h first day, then 200 mg/12 h) on HD 52. Due to acute renal 
failure with refractory metabolic acidosis and hyperkalemia, the patient 
required slow low-efficient daily dialysis. Noradrenaline therapy was 
started due to hemodynamic decompensation. At the time of this report 
the patient remains with hemodynamic and respiratory instability and 
with a serum GM index of 1.01. 
2.4. Case 4 
A 69-year-old insulin-dependent diabetic man came to Posadas 
Hospital due to pneumonia associated with confirmed diagnosis of 
SARS-CoV-2. Chest X-ray revealed bilateral infiltrates. He received cef-
triaxone, clarithromycin, and interferon alpha/remdesivir (HD 1, 2 and 
4). On HD 10, he was admitted to the ICU with moderate ARDS (PaO2: 
FiO2 ratio of 126 mm Hg). He was intubated and mechanically venti-
lated. TA cultures were negative. Due to persistence of fever, progressive 
clinical deterioration and worsening of the radiological picture a new 
endotracheal aspiration was obtained on HD 16. TA revealed 
A. fumigatus in culture and showed branching hyphae on direct exami-
nation. Aspergillus LFD was performed from the TA and serum and 
revealed a positive result. Intravenous voriconazole treatment was 
initiated (400 mg/12 h first day, then 200 mg/12 h). At the time of this 
report the patient remains with hemodynamic and respiratory insta-
bility and with a serum GM index of 2.15 and an AT GM index of 0.25. 
2.5. Case 5 
A 69-year-old insulin-dependent diabetic woman with arterial hy-
pertension and obesity came to hospital due to pneumonia associated 
with confirmed diagnosis of SARS-CoV-2. On HD 2, she was admitted to 
the ICU with moderate ARDS (PaO2:FiO2 ratio of 132 mm Hg). She 
received ceftriaxone, clarithromycin, and dexamethasone 8 mg/day. 
Chest X-ray revealed bilateral infiltrates. She was intubated and me-
chanically ventilated. TA cultures were negative. Due to persistence of 
fever, progressive clinical deterioration and worsening of the radiolog-
ical picture a new TA was obtained on HD 15 and showed A. fumigatus in 
culture. Serum GM index determined using Platelia™ Aspergillus was 
performed and revealed a positive result. Intravenous voriconazole 
treatment was initiated (400 mg/12 h first day, then 200 mg/12 h). At 
the time of this report the patient remains with hemodynamic and res-
piratory instability and with a serum GM index of 0.57 and a TA GM 
index of 3.17. 
All described cases fulfilled the IAPA case definitions for the diag-
nosis of CAPA [12], the oncohematologic patient fulfilled the 
EORTC/MSGERC criteria of probable IPA and the remaining four pa-
tients fulfilled the criteria of putative invasive aspergillosis according to 
the AspICU classification defined by Blot et al. for the diagnosis of 
invasive pulmonary aspergillosis in critically ill patients [13]. 
3. Discussion 
Patients infected with SARS-CoV-2 might develop major lung dam-
age due to viral replication, cytokine storm and the exacerbated in-
flammatory responses [10]. It was reported that the severe damage to 
the lung tissue may lead to secondary infections within a median of 17 
days post COVID-10 symptom onset. Some clinicians reported that CAPA 
occurred after a median of 11.5 days (range 8–42) after onset of 
COVID-19 and at a median of 5 days (3–28) after ICU admission [2]. 
Notable most immunocompetent patients who suffer from severe forms 
of COVID-19 have ≥1 underlying comorbidities, such as hypertension, 
diabetes, chronic obstructive pulmonary disease, obesity, chronic renal 
disease, liver disease, pulmonary fibrosis, smoking [14], such as those 
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described in the four immunocompetent patients studied herein. How-
ever, none of these predisposing factors are frequently associated with 
an increased risk for developing fungal infections. The immunocom-
promised patient included in this study was treated for B-cell acute 
lymphocytic leukemia 6 months ago and developed CAPA during 
chemotherapy. 
Among the pathophysiological factors that may be associated with 
IPA in critically ill patients with COVID-19, are included: damage to the 
respiratory epithelium, defective mucociliary activity, and dysfunc-
tional or “paralyzed” local immune response [15]. Furthermore, in the 
case of influenza, which is also associated to IPA in critically ill patients, 
this virus has been documented to produce an immunomodulatory effect 
by inhibiting the formation of the NADPH oxidase complex, inducing a 
temporary situation similar to that of a patient with chronic granulo-
matous disease [16]. Something similar could be happening with critical 
patients with COVID-19 who develop CAPA, although further studies are 
needed. 
In the present study, we report presumptive invasive aspergillosis in 
five COVID-19 patients with moderate to severe ARDS without under-
lying immunocompromising disease in four patients. Ground-glass 
opacities that characterize COVID-19 as well as IPA were observed in 
all patients that have undergone chest CT scan. To prevent missing IPA, 
a microbiological evaluation at the mycology laboratory is mandatory (i. 
e. testing for the presence of Aspergillus sp. or other fungi in lower res-
piratory secretions and galactomannan in consecutive serum samples in 
COVID-19 ICU patients). 
We identified A. fumigatus in three patients (patients 2, 4 and 5), in 
four patients the Aspergillus 
antigen GM was found positive on TA (patient 1, 3, 4 and 5) and in all 
patients the GM antigen was positive in serum samples. One patient had 
a pre-existing lung disease, one was EORTC/MSGERC host factor posi-
tive [2] and three exhibited ≥ 1 underlying comorbidities (diabetes, 
obesity, arterial hypertension). All patients received corticosteroids 
before ICU admission, however less than 0.3 mg/kg during a short 
period of time (<three weeks). 
No other immunosuppressive medication was given before CAPA 
diagnosis, except to the oncohematologic patient. CAPA occurred after a 
median of 22 days (range 13–52) post COVID-19 symptoms onset and at 
a median of 12 days (2–32) after ICU admission. Chest scan was per-
formed in all patients, with apparent signs of fungal infection. It is 
noteworthy that all patients except one, were male with a median age of 
52.4 years (range 23–69), a younger median age than that reported in 
the literature [17–19]. 
Because all patients with clinical features of probable CAPA were 
suffering from moderate-to-severe respiratory failure and hemodynamic 
instability, antifungal therapy was initiated as soon as cultures or GM 
assays were positive. 
Voriconazole was initiated in four patients and the remaining one 
received liposomal amphotericin B because of severe liver dysfunction. 
One patient (20%) died on treatment at 13 ICU days. 
The diagnosis of IPA in critically ill patients with COVID-19 in ICUs 
still remains a challenge. A decade ago, the H1N1 pandemic showed that 
patients with ARDS triggered by this viral infection were prone to IPA 
and that mortality rates were significantly higher for influenza patients 
who are co-infected with Aspergillus sp. Diagnostic algorithms for pa-
tients admitted to the ICU with and without influenza infection have 
been proposed and are indeed of value in the patient with CAPA [12]. 
However, the limited use of bronchoscopy, makes that diagnosis of 
CAPA usually relies on detection of Aspergillus in upper respiratory tract 
specimens such as sputum or TAs, which may represent airway coloni-
zation rather than IPA. Diagnostic uncertainty is further increased by 
frequent negative serum GM, even in patients with proven CAPA as well 
as the observation of survival of Aspergillus positive patients who did not 
receive antifungal therapy [20]. 
Finally, SARS-CoV-2 infection should be considered a risk factor for 
IPA and early diagnosis and prompt treatment for CAPA in ICU patients 
could help to improve patients’ outcomes due to the high mortality rates 
associated to this invasive fungal disease. 
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